Alliances
In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses.
Shares of Cellectis Therapeutics were up nearly 10% in premarket trading after the company forged a deal with Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.
AbbVie committed up to another $300 in potential milestone payments.
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient’s hands.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
Pfizer struck a collaboration and licensing agreement with Belgium-based Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology.
PRESS RELEASES